A retrospective data analysis revealed a significant improvement in overall survival for patients with hepatocellular carcinoma (HCC) and good hepatic function: Child Pugh class A-treated between 1992 and 2013 with the cancer-specific drug sorafenib, together with inhibitors of the renin–angiotensin system as modulators of the ECM [48]. The gene discussed is REN; the disease is hepatocellular carcinoma.